Skip to main content
. Author manuscript; available in PMC: 2012 Oct 17.
Published in final edited form as: J Neuropathol Exp Neurol. 2010 Aug;69(8):850–863. doi: 10.1097/NEN.0b013e3181eac1f5

Figure 5.

Figure 5

c-Myc expression is prominent in polyhydramnios, megalencephaly, symptomatic epilepsy syndrome (PS), type II focal cortical dysplasia (FCD), and tuberous sclerosis complex (TSC) but not control, type I FCD, or cortical dysplasia focal epilepsy (CDFE) cortex. c-Myc expression in neocortical brain tissue samples (large panel photos, 5x objective; bar = 200 mm; inset photos, 40x objective; bar = 50 mm). c-Myc immunoreactivity is virtually absent in control (A), type I FCD (B), and CDFE (C) cases and abundant in PS (D), type II FCD (E), and TSC (F). Bottom left, Western blot analysis of c-Myc showing enhanced expression in FCD IIB and tuber specimen compared with FCD I or postmortem control cortex. Bottom right, cell counts of c-Myc+ cells in postmortem (PM) control, epilepsy (Epi) control, type I FCD, and type II FCD specimens. Counts reflect mean cell number across 3 regions of interest per specimen; mean ± SEM, *p < 0.05).